BHC

With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

Consumer confidence fell 6.7% to 81.9 in September 2026, hitting its lowest level since April 2014, driven by concerns about labor market conditions and Middle East geopolitical tensions. The Federal Reserve hiked interest rates by 25 basis points and hinted at further increases. In response, four defensive stocks from healthcare and consumer staples sectors are recommended: Bausch Health Companies, CareDx, Dole, and The Chefs' Warehouse.

The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.